J. Cosin and J. Diez, Torasemide in chronic heart failure: results of the TORIC study, European Journal of Heart Failure, vol.35, issue.4, pp.507-513, 2002.
DOI : 10.1016/S0008-6363(97)00091-6

A. Fortuno, P. Muniz, S. Ravassa, J. Rodriguez, and M. Fortuno, Torasemide Inhibits Angiotensin II??Induced Vasoconstriction and Intracellular Calcium Increase in the Aorta of Spontaneously Hypertensive Rats, Hypertension, vol.34, issue.1, pp.138-143, 1999.
DOI : 10.1161/01.HYP.34.1.138

P. Muniz, A. Fortuno, G. Zalba, M. Fortuno, and J. Diez, Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth, Nephrology Dialysis Transplantation, vol.16, issue.suppl 1, pp.14-17, 2001.
DOI : 10.1093/ndt/16.suppl_1.14

T. Uchida, H. Kido, K. Yamanaga, M. Okita, and M. Watanabe, A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.45, issue.2, pp.121-124, 1992.
DOI : 10.1016/0952-3278(92)90227-A

T. Uchida, K. Yamanaga, M. Nishikawa, Y. Ohtaki, and H. Kido, Anti-aldosteronergic effect of torasemide, European Journal of Pharmacology, vol.205, issue.2, pp.145-150, 1991.
DOI : 10.1016/0014-2999(91)90812-5

N. Farman and M. Rafestin-oblin, Multiple aspects of mineralocorticoid selectivity, Am J Physiol Renal Physiol, vol.280, pp.181-192, 2001.

S. Messaoudi, F. Azibani, C. Delcayre, and F. Jaisser, Aldosterone, mineralocorticoid receptor, and heart failure, Molecular and Cellular Endocrinology, vol.350, issue.2, pp.266-272, 2012.
DOI : 10.1016/j.mce.2011.06.038

B. Pitt, F. Zannad, W. Remme, R. Cody, and A. Castaigne, The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure, New England Journal of Medicine, vol.341, issue.10, pp.709-717, 1999.
DOI : 10.1056/NEJM199909023411001

B. Pitt, W. Remme, F. Zannad, J. Neaton, and F. Martinez, Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction, New England Journal of Medicine, vol.348, issue.14, pp.1309-1321, 2003.
DOI : 10.1056/NEJMoa030207

F. Zannad, J. Mcmurray, H. Krum, D. Van-veldhuisen, and K. Swedberg, Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms, New England Journal of Medicine, vol.364, issue.1, pp.11-21, 2011.
DOI : 10.1056/NEJMoa1009492

B. Lopez, R. Querejeta, A. Gonzalez, J. Beaumont, and M. Larman, Impact of Treatment on Myocardial Lysyl Oxidase Expression and Collagen Cross-Linking in Patients With Heart Failure, Hypertension, vol.53, issue.2, pp.236-242, 2009.
DOI : 10.1161/HYPERTENSIONAHA.108.125278

B. Lopez, A. Gonzalez, J. Beaumont, R. Querejeta, and M. Larman, Identification of a Potential Cardiac Antifibrotic Mechanism of Torasemide in Patients With Chronic Heart Failure, Journal of the American College of Cardiology, vol.50, issue.9, pp.859-867, 2007.
DOI : 10.1016/j.jacc.2007.04.080

B. Lopez, R. Querejeta, A. Gonzalez, E. Sanchez, and M. Larman, Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure, Journal of the American College of Cardiology, vol.43, issue.11, pp.2028-2035, 2004.
DOI : 10.1016/j.jacc.2003.12.052

X. Ou, J. Storring, N. Kushwaha, and P. Albert, Heterodimerization of Mineralocorticoid and Glucocorticoid Receptors at a Novel Negative Response Element of the 5-HT1A Receptor Gene, Journal of Biological Chemistry, vol.6, issue.17, pp.14299-14307, 2001.
DOI : 10.1073/pnas.96.26.14724

C. Aguilar-sanchez, I. Hernandez-diaz, F. Lorenzo-diaz, J. Navarro, and T. Hughes, Identification of Permissive Insertion Sites for Generating Functional Fluorescent Mineralocorticoid Receptors, Endocrinology, vol.153, issue.7, pp.3517-3525, 2012.
DOI : 10.1210/en.2012-1210

G. Fejes-toth and A. Naray-fejes-toth, Early Aldosterone-Regulated Genes in Cardiomyocytes: Clues to Cardiac Remodeling?, Endocrinology, vol.148, issue.4, pp.1502-1510, 2007.
DOI : 10.1210/en.2006-1438

F. Gouilleux, B. Sola, B. Couette, and H. Richard-foy, Cooperation between structural elements in hormonoregulated transcription from the mouse mammary tumor virus promoter, Nucleic Acids Research, vol.19, issue.7, pp.1563-1569, 1991.
DOI : 10.1093/nar/19.7.1563

A. Ouvrard-pascaud, S. Puttini, Y. Sainte-marie, R. Athman, and V. Fontaine, Conditional gene expression in renal collecting duct epithelial cells: use of the inducible Cre-lox system, AJP: Renal Physiology, vol.286, issue.1, pp.180-187, 2004.
DOI : 10.1152/ajprenal.00301.2002

M. Pfaffl, A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acids Research, vol.29, issue.9, p.45, 2001.
DOI : 10.1093/nar/29.9.e45

G. Fejes-toth, D. Pearce, and A. Naray-fejes-toth, Subcellular localization of mineralocorticoid receptors in living cells: Effects of receptor agonists and antagonists, Proceedings of the National Academy of Sciences, vol.109, issue.4, pp.2973-2978, 1998.
DOI : 10.1210/mend-5-2-217

C. Latouche, Y. Sainte-marie, M. Steenman, C. Chaves, P. Naray-fejes-toth et al., Molecular Signature of Mineralocorticoid Receptor Signaling in Cardiomyocytes: From Cultured Cells to Mouse Heart, Endocrinology, vol.151, issue.9, pp.4467-4476, 2010.
DOI : 10.1210/en.2010-0237

J. Butler, J. Ezekowitz, S. Collins, M. Givertz, and J. Teerlink, Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee, Journal of Cardiac Failure, vol.18, issue.4, pp.265-281, 2012.
DOI : 10.1016/j.cardfail.2012.02.005

J. Taylor, The 2012 ESC Guidelines on Heart Failure, Eur Heart J, vol.33, pp.1703-1704, 2012.

E. Riddle, R. Schwartzman, M. Bond, and P. Insel, Multi-Tasking RGS Proteins in the Heart: The Next Therapeutic Target?, Circulation Research, vol.96, issue.4, pp.401-411, 2005.
DOI : 10.1161/01.RES.0000158287.49872.4e

H. Lijnen, Pleiotropic functions of plasminogen activator inhibitor-1, Journal of Thrombosis and Haemostasis, vol.268, issue.1, 2005.
DOI : 10.1172/JCI200318038

B. Gooptu and D. Lomas, Conformational Pathology of the Serpins: Themes, Variations, and Therapeutic Strategies, Annual Review of Biochemistry, vol.78, issue.1, pp.147-176, 2009.
DOI : 10.1146/annurev.biochem.78.082107.133320

M. Schellings, Y. Pinto, and S. Heymans, Matricellular proteins in the heart: possible role during stress and remodeling, Cardiovascular Research, vol.64, issue.1, pp.24-31, 2004.
DOI : 10.1016/j.cardiores.2004.06.006

J. Mao, G. Taylor, W. Dean, D. Wagner, and V. Afzal, Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition, Nature Genetics, vol.30, issue.4, pp.421-425, 2002.
DOI : 10.1038/ng850

A. Mackiewicz and K. Mackiewicz, Glycoforms of serum ?1-acid glycoprotein as markers of inflammation and cancer, Glycoconjugate Journal, vol.105, issue.3, pp.241-247, 1995.
DOI : 10.1007/BF00731326

G. Engstrom, B. Hedblad, P. Tyden, and F. Lindgarde, Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: A population-based cohort study, Atherosclerosis, vol.202, issue.2, pp.617-622, 2009.
DOI : 10.1016/j.atherosclerosis.2008.05.038

B. Couette, V. Marsaud, E. Baulieu, and H. Richard-foy, Spironolactone, an aldosterone antagonist, acts as an antiglucocorticosteroid on the mouse mammary tumor virus promoter., Endocrinology, vol.130, issue.1, pp.430-436
DOI : 10.1210/endo.130.1.1309341

F. Rogerson, Y. Yao, B. Smith, N. Dimopoulos, and P. Fuller, Determinants of spironolactone binding specificity in the mineralocorticoid receptor, Journal of Molecular Endocrinology, vol.31, issue.3, pp.573-582, 2003.
DOI : 10.1677/jme.0.0310573

A. Mihailidou, L. Le, T. Mardini, M. Funder, and J. , Glucocorticoids Activate Cardiac Mineralocorticoid Receptors During Experimental Myocardial Infarction, Hypertension, vol.54, issue.6, pp.1306-1312, 2009.
DOI : 10.1161/HYPERTENSIONAHA.109.136242

C. Stier and . Jr, Mineralocorticoid Receptors in Myocardial Infarction, Hypertension, vol.54, issue.6, pp.1211-1212, 2009.
DOI : 10.1161/HYPERTENSIONAHA.109.140384

C. Massaad, M. Lombes, M. Aggerbeck, M. Rafestin-oblin, and R. Barouki, Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone, Mol Pharmacol, vol.51, pp.285-292, 1997.

T. Goodfriend, D. Ball, W. Oelkers, and V. Bahr, Torsemide inhibits aldosterone secretion in vitro, Life Sciences, vol.63, issue.3, pp.45-50, 1998.
DOI : 10.1016/S0024-3205(98)00265-3

T. Tsutamoto, H. Sakai, A. Wada, C. Ishikawa, and K. Ohno, Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure, Journal of the American College of Cardiology, vol.44, issue.11, pp.2252-2253, 2004.
DOI : 10.1016/j.jacc.2004.09.009

M. Satoh, M. Nakamura, H. Saitoh, H. Satoh, and T. Akatsu, Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart, Clinical Science, vol.102, issue.4, pp.381-386, 2002.
DOI : 10.1042/cs1020381

Y. Hori, F. Takusagawa, H. Ikadai, M. Uechi, and F. Hoshi, Effects of oral administration of furosemide and torsemide in healthy dogs, American Journal of Veterinary Research, vol.68, issue.10, pp.1058-1063, 2007.
DOI : 10.2460/ajvr.68.10.1058

M. Yamato, T. Sasaki, K. Honda, M. Fukuda, and O. Akutagawa, Effects of Torasemide on Left Ventricular Function and Neurohumoral Factors in Patients With Chronic Heart Failure, Circulation Journal, vol.67, issue.5, pp.384-390, 2003.
DOI : 10.1253/circj.67.384

M. Uechi, M. Matsuoka, E. Kuwajima, T. Kaneko, and K. Yamashita, The Effects of the Loop Diuretics Furosemide and Torasemide on Diuresis in Dogs and Cats, Journal of Veterinary Medical Science, vol.65, issue.10, pp.1057-1061, 2003.
DOI : 10.1292/jvms.65.1057

M. Oyama, G. Peddle, C. Reynolds, and G. Singletary, Use of the loop diuretic torsemide in three dogs with advanced heart failure, Journal of Veterinary Cardiology, vol.13, issue.4, pp.287-292, 2011.
DOI : 10.1016/j.jvc.2011.10.001